SGLT2 inhibitor benefits cardiac patients without diabetes: study

Research suggests gliflozins may do more than lower glucose

Patients with heart failure who don’t have diabetes benefit from being prescribed dapagliflozin as much as those with the disease, suggests a ground-breaking study.